Epigenetics Diagnostic Market Analysis, Size, Growth, Share, Trend, Outlook & Forecast to 2026
The global epigenetics diagnostic market size is expected to reach USD 21.7 billion by 2026, expanding at a CAGR of 18.8% over the forecast period, according to a new study by Grand View Research, Inc. Growing prevalence of cancer and other diseases across the globe, along with epigenetic modification base, is anticipated to fuel the industry growth during the forecast period. Diagnostic companies are upgrading their products by implementing new techniques for attaining specific and sensitive results. Companies such as Abcam plc, Invitrogen, and Sigma Aldrich Corporation are developing a new range of Chromatin immunoprecipitation (ChIP)validated antibodies specific for detection of histone modifications at various loci. In addition, many biotechnology and pharmaceutical companies and academic research organizations are collaborating to promote the growth of the epigenetics diagnostic industry. Companies such as Epigenomics, OncoMethylome Sciences, and Orion Genomics have collaborated with other laboratories and diagnostic companies that have licensed their technology for development of Laboratory-developed Tests (LDTs). Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/epigeneticsdiagnostic-market
Technological advancements resulting in increased accuracy, portability, and cost-effectiveness are expected to be a high-impact rendering driver in the market. For instance, Diagenode has developed automated kits for detection and purification of methylated DNA. Further key findings from the study suggest:
On the basis of product, reagents held the largest share owing to increasing R&D activities in field of epigenetics. Kits are expected to witness high demand over the forecast period, expanding at a CAGR of 19.2% due to need for rapid and accurate detection techniques
Based on technology, DNA methylation held a major share in terms of revenue in 2018. Technological advancements such as Methylation Sensitive PCR (MSP) and rapid adoption of these products to improve diagnostics efficiency are the factors attributing to its largest share
Growing prevalence of cancer with epigenetic modification is a key factor driving the oncology application segment. Solid tumors further dominated the segment in 2018
North America emerged as a major regional market in 2018 due to factors such as high levels of patient awareness, growing collaborations between large pharmaceutical firms for development of improved therapeutics, increasing funding for R&D, and increasing cancer prevalence
The market in Asia Pacific is estimated to witness significant growth over the forecast period with a CAGR of 20.9% owing to the presence of large target population having cancer, diabetes, and other chronic disorders, along with parallel unmet clinical needs
Major players of the industry include Sigma-Aldrich Corporation; Valirx Plc; Oncolys Biopharma Inc.; Zymo Research Corporation; Qiagen; Thermo Fisher Scientific; Diagenode Diagnostics; and Illumina, Inc. Extensive R&D initiatives for development of novel drugs and presence of strong product pipeline are expected to further boost the market growth over the forecast period.
Grand View Research has segmented the global epigenetics diagnostic market on the basis of product, technology, application, and region: Epigenetics Diagnostic Product Outlook (Revenue, USD Million, 2014 - 2026) Reagents
Kits o
ChIP Sequencing Kit
o
Whole Genomic Amplification Kit
o
Bisulfite Conversion Kit
o
RNA Sequencing Kit
o
Others
Instruments
Enzymes
Services
Epigenetics Diagnostic Technology Outlook (Revenue, USD Million, 2014 - 2026) DNA Methylation
o
Reagents
o
Kits
o
Instruments
o
Enzymes
o
Services
Histone Methylation o
Reagents
o
Kits
o
Instruments
o
Enzymes
o
Services
Histone Acetylation o
Reagents
o
Kits
o
Instruments
o
Enzymes
o
Services
Large non-coding RNA o
Reagents
o
Kits
o
Instruments
o
Enzymes
o
Services
MicroRNA modification o
Reagents
o
Kits
o
Instruments
o
Enzymes
o
Services
Chromatin structures o
Reagents
o
Kits
o
Instruments
o
Enzymes
o
Services
What questions do you have? Get quick response from our industry experts @ https://www.grandviewresearch.com/request-free-consultation/5811/rfc
Epigenetics Diagnostic Application Outlook (Revenue, USD Million, 2014 – 2026) Oncology
o
Solid tumors
o
Liquid tumors
Non-oncology o
Inflammatory diseases
o
Metabolic diseases
o
Infectious diseases
o
Cardiovascular diseases
o
Others
Epigenetics Diagnostic Regional Outlook (Revenue, USD Million, 2014 - 2026) North America
o
U.S.
o
Canada
Europe o
U.K.
o
Germany
o
Spain
o
France
o
Italy
o
Russia
Asia Pacific o
Japan
o
China
o
India
o
South Korea
o
Singapore
o
Australia
Latin America o
Brazil
o
Mexico
o
Argentina
Middle East and Africa (MEA) o
South Africa
o
United Arab Emirates
o
Saudi Arabia
Table of Content Chapter 1 Research methodology 1.1 Market segmentation & scope 1.2 Market definition 1.3 Information procurement i. Purchased database ii. GVR’s internal database iii. Secondary sources & third-party perspectives iv. Primary research 1.4 Information analysis i. Data analysis models 1.5 Market formulation & data visualization 1.6 Data validation & publishing Chapter 2 Executive summary
2.1 Epigenetics Diagnostic Market Outlook 2.2 Segment Outlook 2.3 Competitive Insights Chapter 3 Global Epigenetics Diagnostic Market Variables, Trends & Scope 3.1 Penetration & Growth Prospects Mapping 3.2 Regulatory Framework 3.2.1 Reimbursement framework 3.2.2 Standards & Compliances 3.3 Epigenetics Diagnostic Market Dynamics Continue……….. About Grand View Research, Inc.: Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact: Sherry James Corporate Sales Specialist, USA Grand View Research, Inc Phone: 1-415- 349-0058 Toll Free: 1-888- 202-9519 Email: sales@grandviewresearch.com For More Information: http://www.grandviewresearch.com